1/29
Vocabulary practice flashcards covering drug mechanisms, antibacterial targets, adverse effects, and antimycobacterial therapy from Lecture 7: Antimicrobial Chemotherapy.
Selective toxicity
The ability of an antimicrobial agent to inhibit or kill a pathogen by exploiting biochemical or structural differences between the bacterium and human host cells (such as targeting bacterial cell walls).
Intrinsic resistance
A natural, inherent characteristic of a bacterial species that renders it immune to an antibiotic's action (for example, a bacterium that naturally lacks a cell wall is insusceptible to penicillin).
Acquired resistance
A mechanism by which previously susceptible bacteria survive antibiotic exposure due to spontaneous genetic mutations or the acquisition of exogenous resistance genes.
Penicillin-binding proteins (PBPs)
Bacterial enzymes that catalyze the cross-linking of peptidoglycan strands to provide structural rigidity to the cell wall; the target blocked by β-lactams.
β-lactams
A class of cell-wall inhibitors comprising penicillins, cephalosporins, monobactams, and carbapenems that bind to PBPs, preventing peptidoglycan cross-linking and weakening the cell wall.
Superinfection
A secondary infection that develops during or following antimicrobial treatment, often occurring when broad-spectrum antibiotics eliminate normal flora and allow opportunists like yeast to overgrow.
β-lactamase
A bacterial resistance enzyme that hydrolyzes and breaks the core β-lactam ring of susceptible antibiotics, rendering them inactive.
β-lactamase inhibitors
Agents including clavulanate, sulbactam, and tazobactam that inhibit bacterial β-lactamase enzymes to prevent the degradation of partnered β-lactam antibiotics.
Translocation (ribosomal)
The forward movement of the bacterial ribosome along mRNA as the tRNA bearing the elongated polypeptide shifts from the ribosomal A site toward the P site.
Tetracyclines
Protein-synthesis inhibitors (such as tetracycline, doxycycline, and minocycline) that bind to the 30S ribosomal subunit and physically block incoming aminoacyl-tRNA from entering the A site.
Chelation (antimicrobial)
The binding of polyvalent mineral cations (such as calcium, iron, and magnesium) to antibiotics like tetracyclines within the gastrointestinal tract, significantly decreasing oral drug absorption.
Aminoglycosides
Bactericidal protein-synthesis inhibitors (including gentamicin, streptomycin, and neomycin) that bind irreversibly to the 30S ribosomal subunit, causing mRNA misreading and disrupting translocation.
Ototoxicity
Auditory or vestibular damage characterized by dizziness, hearing changes, or ringing in the ears (tinnitus); a key adverse effect associated with gentamicin therapy.
Nephrotoxicity
Kidney damage marked by elevations in serum creatinine levels, necessitating ongoing monitoring of renal function during aminoglycoside administration.
Neuromuscular blockade
Interference with signal transmission from nerves to muscles; a rare, severe adverse effect of aminoglycosides that can compromise respiratory musculature.
Chloramphenicol
A broad-spectrum antibiotic that binds to the 50S ribosomal subunit to inhibit peptidyl transferase, thereby halting peptide bond formation between incoming amino acids.
Bone marrow depression
A significant adverse effect associated with chloramphenicol that decreases blood cell production, causing anaemia, increased susceptibility to infection, and easy bruising, monitored via CBC.
DNA gyrase (topoisomerase II)
A bacterial enzyme that relieves excessive positive supercoiling and torsional strain ahead of replicating DNA; a primary target inhibited by fluoroquinolones.
Topoisomerase IV
A bacterial enzyme essential for untangling, decatenating, and separating duplicated daughter DNA chromosomes during cell division; inhibited by fluoroquinolones.
Fluoroquinolones
Antimicrobial agents (e.g., ciprofloxacin, norfloxacin, clinafloxacin) that trap bacterial topoisomerases while DNA is cleaved, causing lethal breaks; strongly linked to tendinitis and Achilles tendon pain.
Sulfamethoxazole
A sulfonamide antimetabolite that competes structurally with PABA for the enzyme dihydropteroate synthase (folic acid synthetase) to disrupt early bacterial folate synthesis (PABA→DHF).
Trimethoprim
An antifolate drug that selectively inhibits bacterial dihydrofolate reductase (DHFR), blocking the reduction of DHF to active THF (DHF→THF).
Sequential blockade
A synergistic mechanism in which two drugs inhibit two consecutive enzymatic steps in the same metabolic cascade, as demonstrated by co-trimoxazole combining sulfamethoxazole and trimethoprim.
Daptomycin
A lipopeptide antimicrobial agent classified as a cell-membrane disruptor that dissipates the bacterial membrane electrical balance, leading to the rapid failure of critical cellular processes and cell death.
Mycolic acids
Long-chain fatty acids that constitute the protective, waxy outer envelope of mycobacteria, the biosynthesis of which is selectively inhibited by isoniazid.
Rifampin
A first-line antimycobacterial agent that inhibits bacterial DNA-dependent RNA polymerase; notably causes benign orange-red discoloration of body secretions (sweat, tears, urine) and carries risk of hepatotoxicity.
Isoniazid (INH)
An antimycobacterial drug that blocks mycolic acid assembly; linked to peripheral neuropathy (paresthesias in hands/feet) that can be mitigated by co-prescribing vitamin B6.
Pyrazinamide
A core tuberculosis agent effective against dormant or slowly multiplying bacilli sequestered in acidic bodily environments; known to cause arthralgia, hyperuricemia, and hepatotoxicity.
Ethambutol
An antimycobacterial drug that halts mycobacterial cell wall synthesis; its principal toxicity is optic neuropathy causing reduced visual acuity, blurred vision, or impaired color vision.
Dapsone
An antifolate antimicrobial structurally analogous to sulfonamides that suppresses folate synthesis in Mycobacterium leprae, used in combination therapy with rifampicin and clofazimine.